CLOV241213P4500
- 1.30
- +0.07+5.69%
Clover Health Newsroom
CCORF Maintains Clover Health(CLOV.US) With Buy Rating, Raises Target Price to $4.2
Clover Health Investments: Strong EBITDA Performance Amid Rising Medical Costs and Revenue Challenges Justifies Hold Rating
Clover Health: A Strong Buy on 4-Star Rating and Competitive Edge
Clover Health Investments Price Target Announced at $4.00/Share by UBS
Clover Health Investments Analyst Ratings
Clover Health Initiated With a Neutral at UBS
CCORF Maintains Clover Health(CLOV.US) With Buy Rating, Raises Target Price to $3.2
Cautious Optimism Amidst Clover Health's Strong Quarter: A Hold Recommendation With Revised Price Target
Buy Rating Affirmed for Clover Health on Strong Commercial Potential of Clover Assistant Technology
Cautious Optimism Tempered by Sustainability Concerns: Analyst Upholds Hold Rating on Clover Health Investments
Clover Health's Positive Trajectory: A Buy Rating With a Focus on Sustained Profitability
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
Clover Health Investments: Hold Rating With High Risk Amidst Progress Towards Stability
Analysts' Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV) and Biomea Fusion (BMEA)
Hold Rating on Clover Health Investments: Performance Upsides, Growth Concerns, and Capital Risk Factors
Hold Rating on Clover Health: Mixed Financial Performance and Future Uncertainty
Citigroup Maintains Neutral on Clover Health Investments, Raises Price Target to $1.5
Clover Health Investments Analyst Ratings
Clover Health Investments (CLOV) Receives a Sell From Bank of America Securities
SVB Securities Remains a Hold on Clover Health Investments (CLOV)